MedTrace Logo

Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria

NCT04833855 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 183

Last updated 2025-04-09

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to evaluate the effect of tezepelumab on improvement in the Urticaria Activity Score over 7 days (UAS7).

Conditions

Interventions

BIOLOGICAL

Tezepelumab Dose 1

Subcutaneous injection.

BIOLOGICAL

Tezepelumab Dose 2

Subcutaneous injection.

BIOLOGICAL

Omalizumab

Subcutaneous injection.

BIOLOGICAL

Placebo

Subcutaneous injection.

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-15
Primary Completion
2022-12-20
Completion
2023-04-13
FDA Drug
Yes

Countries

  • United States
  • Canada
  • France
  • Germany
  • Greece
  • Italy
  • Japan
  • Poland
  • South Korea
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04833855 on ClinicalTrials.gov